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Level (CUPID) Study GroupAbstract
Background: Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in
dialyzed patients.
Objectives: The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin
D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally,
we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23.
Design: Multicenter, open-labeled, randomized controlled study.
Setting: Seven university-affiliated hospitals in Korea.
Participants: Overall, 66 peritoneal dialysis patients were enrolled.
Intervention: Sixty six patients were randomly assigned to treatment with either cinacalcet + oral vitamin D
(cinacalcet group, n = 33) or oral vitamin D alone (control group, n = 33) to achieve K/DOQI targets. CUPID
included a 4-week screening for vitamin D washout, a 12-week dose-titration, and a 4-week assessment phases. We
calculated mean values of iPTH, Ca, P, Ca x P, during assessment phase and final FGF23 to assess the outcome.
Main outcome measures: Achievement of >30% reduction of iPTH from baseline (primary) and FGF23 reduction
(secondary).
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Results: 72.7% (n = 24) of the cinacalcet group and 93.9% (n = 31) of the control group completed the study.
Cinacalcet group received 30.2 ± 18.0 mg/day of cinacalcet and 0.13 ± 0.32 μg/d oral vitamin D (P < 0.001 vs.
control with 0.27 ± 0.18 μg/d vitamin D). The proportion of patients who reached the primary endpoint was not
statistically different (48.5% vs. 51.5%, cinacalcet vs. control, P = 1.000). After treatment, cinacalcet group
experienced a significant reduction in FGF23 levels (median value from 3,960 to 2,325 RU/ml, P = 0.002), while an
insignificant change was shown for control group (from 2,085 to 2,415 RU/ml). The percent change of FGF23 after
treatment was also significantly different between the two groups (− 42.54% vs. 15.83%, P = 0.008). After
adjustment, cinacalcet treatment was independently associated with the serum FGF23 reduction.
Conclusion: Cinacalcet treatment was independently associated with the reduction of FGF23 in our PD patients.
Trial registration: Controlled trials NCT01101113
Keywords: Cinacalcet, Fibroblast growth factor 23, Peritoneal dialysisBackground
Fibroblast growth factor-23 (FGF23) is an endocrine hor-
mone that regulates phosphate and vitamin D homeostasis.
FGF23 is synthesized and secreted by bone cells, mainly
osteocytes and plays a role as a phosphatonin by binding
to klotho/FGF-receptor complex [1,2]. FGF23 inhibits
phosphate reabsorption in the renal tubule and pro-
motes phosphaturia by down-regulating sodium-phosphate
co-transporters [3]. It decreases renal production of 1,25
(OH)2D by inhibiting 1α-hydroxylase and up-regulating
24-hydroxylase in the proximal tubule [3,4]. As kidney
function decreases in chronic kidney disease (CKD) pa-
tients, FGF23 increases progressively in order to regulate
phosphate homeostasis [5]. In advanced CKD, FGF23 no
longer maintains phosphate homeostasis and the suppres-
sion of 1,25(OH)₂D production exerted by FGF23 induces
PTH elevation, resulting in secondary hyperparathyroidism
(SHPT). Several studies reported that high levels of FGF23
are related to left ventricular hypertrophy [6-9] and
progression of chronic kidney disease [10]. Furthermore,
FGF23 elevation is associated with increased mortality in
CKD and ESRD patients [11]. Therefore, in CKD patients,
modulation of FGF23 could possibly be a therapeutic target
in preventing morbidity and mortality. Cinacalcet hydro-
chloride is a novel calcimimetics that acts by allosteric
binding to the calcium sensing receptor on the parathyroid
cell membrane and thus lowering PTH. To date, several
studies reported that cinacalcet reduced FGF23 in
predialysis or hemodialysis patients [12,13].
It was shown that FGF23 levels are independently corre-
lated with serum concentrations of P, Ca x P, and serum
parathyroid hormones (PTH). Recently, a few clinical trials
on the efficacy of cinacalcet on the lowering of PTH
exhibited that cinacalcet treatment lowers FGF23 in ESRD
patients [12,13]. However, above studies have not eluci-
dated whether FGF23 suppression during cinacalcet treat-
ment is mediated indirectly via the modulation of serum Pand PTH or directly by cinacalcet per se. The aim of the
Cinacalcet study for Peritoneal Dialysis Patients In Double
Arm on the Lowing Effect Of iPTH Level (CUPID) Trial
(NCT01101113, registered at the http://www.clinicaltrials.
gov) is to investigate the effectiveness of a cinacalcet-based
regimen versus vitamin D based regimen in treating
SHPT, controlling PTH, Ca, and P levels for achieving the
K/DOQI targets for peritoneal dialysis (PD) patients. Add-
itionally, we also investigated whether the cinacalcet effect
on the FGF23 suppression occurs directly, independent of
its modulation of Ca, P, PTH and exposure to vitamin D.
Methods
Study population
Seven university-affiliated hospitals in Korea partici-
pated in the CUPID trial. Patients were considered for
the study if they were ≥18 and ≤70 years of age, had re-
ceived peritoneal dialysis (PD) for ≥3 months and with
pre-screening intact PTH (iPTH) ≥300 pg/ml (≥250 pg/ml
if they had been taking vitamin D analogs) and albumin–
corrected calcium ≥9.0 mg/dl. After a 4-week washout
period during which vitamin D was withheld, iPTH
and calcium levels were measured again. Patients with
post-washout iPTH ≥300 pg/ml and corrected calcium
≥9.0 mg/dl were finally enrolled in the study.
Patients were excluded if they had acute inflammatory
disease within 3 months, chronic inflammatory disease,
gastrointestinal bleeding within 3 months, and were preg-
nant or breast feeding. Patients who had been taking azole
antifungal agents, macrolide antibiotics, amiodarone, tri-
cyclic antidepressant, vinca alkaloid, bupropion antipsy-
chotics, calcitonin, biosphosphonate, steroid hormones, or
benzodiazepine drugs were excluded. The study adhered
to the principles of the Declaration of Helsinki. The inde-
pendent ethics committee for each participating center
(Seoul National University Hospital Institutional Review
Board; Seoul National University Bundang Hospital
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Hospital Institutional Review Board; Samsung Medical
Center Office of Research Subjects Protection; Gachon
University Gil Medical Center Institutional Review Board;
Hallym University Sacred Heart Hospital Institutional Re-
view Board/Ethics Committee; Eulji University Hospital
Institutional Review Board) approved the study protocol,
and all patients provided written informed consent.
Study design and treatments
This is a multicenter, open-labeled, and randomized
controlled study fulfilled at seven sites. The 20-week
study consisted of three phases: a 4-week screening and
vitamin D washout phase, a 12-week dose-titration
phase, and a 4-week efficacy-assessment phase. At the
end of 4-week screening phase, patients were randomly
assigned at 1:1 ratio to receive either cinacalcet-based
or vitamin D-based therapy. The specific prescription
for the cinacalcet group was adjusted according to the
treatment algorithm (Figure 1). No subjects had ever
taken cinacalcet before screening since cinacalcet was
not available in Korea at the time of the study. After
screening and vitamin D washout phase, cinacalcet
group started with 25 mg/day of cinacalcet (Regpara;
Kyowa Hakko Kirin, Co., Ltd, Tokyo, Japan) p.o. and the
cinacalcet dose was, in a stepwise pattern, increased at a
4-week interval to 50 mg/day to achieve an iPTH target
between 150 and 300 pg/ml. There was no dosage
increase within 4 weeks after starting a 25 mg dose, or if
the corrected Ca was ≤8.4 mg/dL. The cinacalcet doseFigure 1 Dose titration algorithm for cinacalcet and vitamin D in the
group started with 25 mg/day of cinacalcet p.o. and the cinacalcet dose w
to achieve an iPTH target between 150 and 300 pg/ml. iPTH, intact parathywas to be reduced if iPTH <150 pg/ml and the dose of
concomitant vitamin D could not be further reduced.
Cinacalcet were withheld if corrected Ca ≤7.5 mg/dL, or
the subjects had symptomatic hypocalcemia, or experi-
enced severe adverse reactions. After starting cinacalcet,
the dose of vitamin D prescription was adjusted by treat-
ment algorithm to attain serum iPTH, Ca, and P targets.
Vitamin D dosage was reduced if iPTH <150 mg/ml or if
iPTH between 150 and 300 with corrected Ca ≥10.2 mg/dL
or P ≥5.5 mg/dL.
The control group received flexible dose of oral active
vitamin D to achieve K/DOQI targets for PTH, Ca, P, and
Ca × P. For active vitamin D, only oral calcitriol, not active
vitamin D analogs, was prescribed for both groups. Phos-
phate binders were allowed to be prescribed at the physi-
cian’s discretion throughout the study for both groups.
The subjects were not allowed to change dialysate calcium
concentration during the entire study period and could
not change cinacalcet and vitamin D dosage during the
efficacy-assessment phase.
Biochemical determinations and FGF23
PTH was measured by intact PTH assays at 4-week in-
tervals. All centers were instructed to use the same type
of PTH assay throughout the entire study period. Serum
Ca, P, and albumin level were measured every 4 weeks
but measured twice at 2-week interval if the dose of
cinacalcet was changed. ‘Baseline values’ of the various
biochemical tests – Ca, P, iPTH, etc. - were defined as
those measured after washout period (post-washout).cinacalcet group during dose-titration period. Initially, cinacalcet
as, in a stepwise pattern, increased at a 4-week interval to 50 mg/day
roid hormone; Ca, calcium; P, phosphorus; Vit D, vitamin D.
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and at the end of assessment phase. Second generation
human FGF23 (C-terminal) ELISA kit (Immutopics, San
Clemente, California, USA) was employed. The serum
was diluted ten-fold with dilution reagent to measure C-
terminal FGF23, since the assay accuracy was not validated
above this dilution level. The assay range was between 1.5
and 14,900 RU/ml. Over-range of FGF23 which could be
not detected after dilution, were excluded in the analysis: 2
patients in the cinacalcet group at baseline; 1 in the control
group at baseline; 1 in the control group at efficacy assess-
ment phase.
Study end points
The mean values of corrected Ca, P, and corrected Ca × P
during assessment period were calculated to analyze the
results. The primary endpoint was the achievement
of >30% reduction of iPTH from baseline. The secondary
end points were the absolute or percent change of FGF23
from baseline and the achievements of the K/DOQI tar-
gets for the iPTH (150~300 pg/ml), Ca (8.4 ~ 9.5 mg/dL),
P (3.5 ~ 5.5 mg/dL), Ca x P (<55 mg2/dL2), and composite
of above targets. We estimated target enrollment to be 85
subjects (based on α= 0.05, β=0.2, and 10% drop-out rate)
in order to prove more than 32% difference between the
treatment and control arms in the achievement of the pri-
mary end point [14].
Statistical analysis
Baseline demographic and mineral metabolic parameters
were analyzed: differences in gender and underlying dis-
eases between treatment groups were evaluated with χ2
tests; patient’s age, duration of dialysis, and baseline pa-
rameters were evaluated with independent samples t-tests.
Results are presented as mean ± SD for normally distri-
buted variables and median [interquartile range (IQR)] for
variables with skewed distributions. A log and square root
transformation was used to normalize variability of the
iPTH and FGF23 data distribution, respectively; log and
square root transformation were implemented before
entry into analysis. The demographic variables, percent
change in Ca, P, log-transformed iPTH, and the vitamin D
dose were used for univariate analysis. Variables showing
a significant association (P <0.01) in the univariate analysis
or of considerable theoretical relevance were retained as
potential predictors in the multivariate model (enter
method). Percent change measures were chosen for ana-
lysis to alleviate the biasing effect of the patient’s baseline
mineral metabolic levels. The percent change was
calculated for each mineral metabolic parameter with
the following formula: [(week 16 measurement – base-
line measurement)/baseline measurement] × 100. Percent
changes of the log iPTH and the square root FGF23were cal-
culated similarly: [(log week 16 measurement – log baselinemeasurement)/log baseline measurement] × 100; [(square
root week 16 measurement – square root baseline meas-
urement)/square root baseline measurement] × 100.
Whether or not the pretreatment (post-washout) FGF23
levels would anticipate the probability of achieving an
iPTH in the range between 150 and 300 pg/ml during the
efficacy assessment phase, were evaluated by logistic re-
gression analysis. P values <0.05 were considered to repre-
sent statistical significance. All statistical analyses were
performed using the SPSS software (version 18.0., SPSS
Inc, Chicago, III, USA).
Results
Study population and baseline parameters
A total of 66 patients were enrolled and randomly
assigned at 1:1 ratio - 33 were assigned to the cinacalcet
group and 33 to the control group. Recruitment ended
prematurely before target enrollment number (n=85)
was reached, since the study underwent insufficiency of
subjects who fulfilled the strict inclusion criteria. Base-
line demographic characteristics, duration of dialysis,
underlying disease, and renal Kt/V before randomization
showed no statistical differences for both groups
(Table 1). Furthermore, the baseline levels for iPTH, Ca,
P, and Ca X P after vitamin D washout, and the FGF23
were similar between both groups. Six (18.2%) of the
cinacalcet group and 11 (33.3%) of the control group
had received active vitamin D (paricalcitol, calcitriol, or
alfacalcidol) before screening. More than two-thirds of
the patients in each group had received phosphate
binders: 28 (84.8%) for the cinacalcet group and 25
(75.6%) for the control group.
Overall, twenty four (72.7%) of the cinacalcet group
and thirty one (93.9%) of the control group completed
the study. Reasons for dropouts included adverse reac-
tions (n = 3 vs. 0, cinacalcet vs. control), withdrawal of
consent (n = 3 vs. 1), kidney transplant (n = 2 vs. 1) and
taking not allowed medication (n = 1 vs. 0). No subjects
in the control group took cinacalcet throughout the
study period.
PTH and biochemical parameters
The median (Q1,Q3) iPTH decreased from 729 pg/ml
(518, 1424 pg/ml) at baseline to 421 pg/ml (267, 753 pg/ml)
during the efficacy assessment phase for the cinacalcet
group, and from 649 pg/ml (490, 1143 pg/ml) to 441 pg/ml
(317, 663 pg/ml) for the control group (Figure 2A). The
median iPTH decreased by 42.3% in the cinacalcet group,
and by 30.7% in the control group (P = 0.483). The pro-
portion of patients who reached the primary endpoint
(30% reduction in mean iPTH from the baseline) was not
statistically different (48.5% vs. 51.5%, cinacalcet vs. con-
trol, P = 1.000). The proportion of patients who achieved
an iPTH target between 150 and 300 pg/ml during the
Table 1 Patient demographics and baseline laboratory values
Characteristic Cinacalcet group (n = 33) Control group (n = 33) P-value
Sex, n (%) 0.324
Male 20 (60.6) 15 (45.5)
Female 13 (39.4) 18 (54.5)
Age, years 0.520
mean (SD) 48.8 (11.5) 47.2 (8.4)
Range 25 to 71 28 to 64
Duration of dialysis, months mean (SD) 78.7 (39.8) 71.3 (40.6) 0.454
Medical history, n (%)
hypertension 32 (97.0) 29 (87.9) 0.355
diabetes mellitus 7 (21.2) 5 (15.2) 0.751
peripheral vascular disease 2 (6.1) 0 (0.0) 0.492
cerebrovascular disease 2 (6.1) 0 (0.0) 0.492
congestive heart failure 1 (3.0) 0 (0.0) 1.000
iPTH, median (Q1,Q3) (pg/ml)* 729 (518, 1424) 649 (490, 1143) 0.783
Serum calcium, mean (SD) (mg/dL)* 9.8 (0.6) 9.6 (0.8) 0.273
Serum phosphorus, mean (SD) (mg/dL)* 5.8 (1.7) 5.3 (1.4) 0.231
Ca X P, mean (SD) (mg2/dL2)* 53.8 (16.3) 48.7 (14.5) 0.189
Serum FGF23 (Q1,Q3) (RU/ml)* 3960 (2430, 6609) 2085 (741, 7182) 0.134
Renal Kt/V (Q1, Q3) 0.0 (0.0, 0.1) 0.0 (0.0, 0.5) 0.170
Peritoneal Kt/V (SD) 1.8 (0.5) 1.8 (0.6) 0.956
Total Kt/V (SD) 1.9 (0.4) 2.1(0.6) 0.124
*Post-washout (week 0) value.
Q1 first quartile, Q3 third quartile.
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(24.3% vs. 18.2%, P = 0.764).
The proportion of patients who achieved Ca × P
<55 mg2/dl2 (54.5% vs. 51.5%, P = 1.000), the Ca target
(54.5% vs. 45.5%, P = 0.623), and P target (30.3% vs.
30.3%, P = 1.000) were similar. In the cinacalcet group,
the Ca × P increased by 5.1% (P = 0.324 vs. control with
14.4%) and P increased by 8.3% in the cinacalcet group
(P = 0.909 vs. control with 7.3%). Only the change of cal-
cium was significantly different (−7.2% vs. 1.1%, cinacalcet
vs. control, P <0.001).
The proportion of patients who achieved K/DOQI tar-
gets for iPTH, Ca, P, Ca × P, and their composite were
not statistically different between two groups.
Effect of cinacalcet on the FGF-23
Cinacalcet group exhibited a significant decrease in
FGF23 levels from 3,960 (2430, 6609) RU/ml at the base-
line to 2,325 (514, 6598) RU/ml during the efficacy assess-
ment phase (shown in median, Q1 and Q3), while the
control group increased from 2,085 (741,7182) RU/ml to
2,415 (740,5191) RU/ml (P = 0.002). The change of FGF23
was significantly different (−42.5% vs. 15.8%, P = 0.008;
Figure 3). Univariate and multivariate linear regression
analyses were undertaken to explore factors correlatedwith the change of FGF23. In univariate linear regression,
only cinacalcet treatment correlated significantly with the
change of FGF23 (P = 0.004) while Ca, P, iPTH levels, and
oral vitamin D dose did not (Table 2). After adjustment to
age and sex, cinacalcet treatment remained an independ-
ent determinant of the serum FGF23 reduction (Table 3).
Within the cinacalcet group, there was no significant
difference in baseline FGF23 levels between the subjects
who achieved iPTH target and those who did not [3870
RU/ml (1100, 5108 RU/ml) vs. 4159 RU/ml (2433, 7376
RU/ml), P = 0.427].
Doses of medications and safety
Cinacalcet group received 30.2 ± 18.0 mg/day of mean
cinacalcet dose during the assessment phase (n = 24).
The vitamin D doses during the assessment phase were
0.13 ± 0.32 μg/d (mean ± SD) in the cinacalcet group
(n = 24, P <0.001) vs. 0.27 ± 0.18 μg/d (n = 31) in the
control group (Figure 4). Phosphate binders were pre-
scribed in 90.9% of the cinacalcet group vs. 81.8%
(P = 0.475) of the control group at initiation of treat-
ment and in 83.3% vs. 90.3% (P = 0.686) during assess-
ment phase. During assessment phase, Ca-containing
phosphate binders were prescribed for the 62.5% of the
cinacalcet group and for the 48.4% of the control group.
Figure 2 Mineral metabolic parameters at each scheduled visit for both groups. Median iPTH (A), mean calcium-phosphorus product (Ca X P)
(B), calcium (Ca) (C), and phosphorus (P) (D). iPTH decreased by 42.3% in the cinacalcet group, and by 30.7% in the control group (P = 0.483). Error
bars denote interquartile range (A), or standard deviation (SD) (B, C, D). iPTH, intact parathyroid hormone; Ca, calcium; P, phosphorus.
Figure 3 Median percent change from baseline to final values
of fibroblast growth factor (FGF23). Cinacalcet group, n = 22;
Control group, n = 30. The change of FGF23 was significantly
different; -42.5% vs. 15.8%, P = 0.008 as compared with control group.
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and 42.4%, respectively.
A total of 51.5% of the cinacalcet group and 33.3% of
the control group experienced at least one adverse event.
The most common adverse reactions were digestive
symptoms. In the cinacalcet group, nausea/vomiting
(18.2%), dyspepsia (3.0%), diarrhea (3.0%), and constipa-
tion (3.0%) were present. For the control group, nausea/
vomiting, and diarrhea (3.0%, each) were most often
observed. There were no significant differences in both
groups. Other adverse reactions in the cinacalcet group
were tingling sensation (6.1%), general weakness (3.0%),
and headache (6.1%). There was no death or other
serious adverse events in the entire study period in
both groups. Severe hypocalcemia (serum corrected cal-
cium <7.5 mg/dl at least once during the entire study
period) occurred in one patient (3.0%) of each group, re-
spectively. However, there was no symptomatic, or fatal
hypocalcemia in both groups. All safety analyses were
performed by intention-to-treat method.
Table 2 Univariate linear regression analysis for association of the percent change in square root FGF23 with other
variables
Variable B coefficient 95% CI P- value
Sex (male vs. female) 3.80 −27.03 to 34.62 0.805
Age (per 1year) 0.51 −1.16 to 2.18 0.540
DM (yer vs. no) 24.36 −16.24 to 64.96 0.233
Treatment (cinacalcet vs control) −42.45 −70.96 to −13.93 0.004
Vitamin D dose (per 1μg/day) 6.65 −49.86 to 63.15 0.814
Log-iPTH (pg/ml)* 0.27 −1.64 to 2.19 0.776
Ca (mg/dL)* 0.31 −1.40 to 2.02 0.718
P (mg/dL)* −0.02 −0.46 to 0.41 0.916
* Percent change from baseline to assessment phase values was used for analysis.
CI confidence interval.
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The purpose of the present study was to investigate the
effectiveness of cinacalcet-based vs. vitamin D based regi-
men in treating SHPT, achieving the K/DOQI targets for
PD patients, and the cinacalcet effect on FGF23 suppre-
ssion. The present study did not show a difference in the
reduction of iPTH since it did not achieve the target
enrollment number. However, the present study exhibited
that serum FGF23 was significantly reduced during
cinacalcet treatment. Moreover, cinacalcet effect on the
FGF23 suppression was independent of its effect on serum
iPTH, Ca, P, and the exposure to oral vitamin D.
Recent studies have shown that high levels of FGF23 are
associated with poor outcomes such as left ventricular
hypertrophy [15,16], progression of CKD [16] and in-
creased overall mortality [17]. FGF23 could be a better
prognosis predictor of cardiovascular disease than any
other biomarkers. Therefore, reduction of FGF23 may be-
come a novel target of treating SHPT for lowering cardio-
vascular risk and improving prognosis of CKD patients.
It is well documented in a few recent randomized
clinical trials that cinacalcet is more efficient than con-
ventional vitamin D based therapy in treating SHPT in
hemodialysis patients [14,18,19]. Furthermore, post hoc
analysis of these studies reported that cinacalcet modu-
lated FGF23 reduction. However, the specific mechanism
of cinacalcet effect on FGF23 suppression has not been
elucidated. Therefore, it remains to be investigated
whether cinacalcet lowers FGF23 per se or indirectly viaTable 3 Univariate and multivariate linear regression
analysis for association of the percent change in square
root FGF23 with treatment groups
B coefficient* (95% CI) P- value
Univariate analysis −42.45 (−70.96 to −13.93) 0.004
Multivariate analysis† −43.58 (−73.07 to −14.09) 0.005
* Treatment effect was analyzed by cinacalcet versus control.
† adjusted for age and sex.
CI confidence interval.modulating other mineral metabolic parameters. Several
studies showed that the cinacalcet group received lower
dose of vitamin D and exhibited lower level of PTH,
compared with those receiving conventional vitamin D
based therapy [14,18]. It is well known that PTH and
vitamin D stimulate FGF23 production [20-22]. There-
fore, one could postulate that the suppression of FGF23
in the cinacalcet group may be associated with lower ex-
posure to vitamin D and lower level of PTH. Koizumi
et al. [13] allowed relatively constant dosage of vitamin
D during the study period. Since the dosage of vitamin
D was allowed to be titrated according to the biochem-
ical parameters in the present study, the cinacalcet
group was prescribed with lower dose of vitamin D than
the control group. However, in our univariate analysis,
neither vitamin D dose nor other mineral metabolic pa-
rameters such as iPTH, Ca and P were associated with
FGF23 change. Cinacalcet treatment was independently
associated with FGF23 reduction, after adjustment to the
age and sex. One could postulate that cinacalcet per se
might have a modulatory effect on the FGF23 level.Figure 4 Mean vitamin D dose at each time point. Error bars
denote standard deviation (SD). *P < 0.05 as compared with
control group.
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of FGF23 reduction with cinacalcet is yet unclear. FGF23
is synthesized and released by bone cells, mainly osteo-
cytes [1,2]. Osteocyte and osteoblast were shown to ex-
press calcium sensing receptor (CaSR). Cinacalcet acts
mainly by allosteric binding to the CaSR on the parathy-
roid cell membrane for regulating calcium homeostasis.
Whether cinacalcet directly acts on the CaSR at the bone
cells to regulate FGF23 secretion needs to be investigated.
The strengths of this study include prospective, ran-
domized study and a design to follow change of FGF23
levels in PD patients with cinacalcet treatment, com-
pared with conventional vitamin D treatment. Moreover,
unlike other study reporting an effect of cinacalcet on
the FGF23 reduction [13], the present study showed an
independent association between cinacalcet treatment
and FGF23 reduction. Unlike the EVOLVE trial, there
was no possibility of cross-over of medication between
the two arms, since cinacalcet was not commercially
available in Korea during the study period [23].
However, the present study has a limitation of a small
sample size and an open-labeled study. The investigators
of the CUPID Study finished the recruitment prematurely
before target number of enrollment was reached. This was
because enrollment was delayed due to lack of subjects
who fulfilled the strict inclusion criteria. This resulted in
lack of statistical power to prove a difference in the iPTH
reduction between two groups, which was the primary
endpoint of the present study. Besides, the prescribed dose
of cinacalcet was 30.2 ± 18.0 mg/day during assessment
phase, which means our subjects received lower dose of
cinacalcet than that reported in other studies [14,18]. This
might be another explanation for the negative result as
regards to the primary end point. Cinacalcet group
exhibited more drop-outs that the control group. The ana-
lysis of FGF23 change was performed on a per-protocol
basis. This may have resulted in a selection bias because
only subjects who were more tolerable to the medication
were included in the analysis. Dietary phosphorus intake,
which is another determinant of serum FGF23 in CKD
[24,25] could not be assessed in the present study. How-
ever, there were no significant differences the prescribed
dose of oral phosphate binders and serum P levels be-
tween the two groups (data not shown). Therefore, we
could postulate that the dietary P intake was similar be-
tween the two groups, although the present study did not
analyze dietary phosphorus intake.
Conclusions
The present study might suggest a more direct association
between serum FGF23 and cinacalcet treatment, inde-
pendent from other mineral metabolic parameters and
vitamin D dose. Mechanistic research is warranted on the
specific mechanism of FGF23 reduction by cinacalcet.Abbreviations
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